MX2021008696A - Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton. - Google Patents
Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton.Info
- Publication number
- MX2021008696A MX2021008696A MX2021008696A MX2021008696A MX2021008696A MX 2021008696 A MX2021008696 A MX 2021008696A MX 2021008696 A MX2021008696 A MX 2021008696A MX 2021008696 A MX2021008696 A MX 2021008696A MX 2021008696 A MX2021008696 A MX 2021008696A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- rheumatoid arthritis
- tyrosine kinase
- lupus erythematosus
- treating rheumatoid
- Prior art date
Links
- 206010072757 chronic spontaneous urticaria Diseases 0.000 title abstract 2
- 208000024376 chronic urticaria Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract 2
- 229940124291 BTK inhibitor Drugs 0.000 title 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 title 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 abstract 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 1
- 229950009618 fenebrutinib Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795477P | 2019-01-22 | 2019-01-22 | |
| US201962913270P | 2019-10-10 | 2019-10-10 | |
| PCT/US2020/014346 WO2020154252A1 (en) | 2019-01-22 | 2020-01-21 | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008696A true MX2021008696A (es) | 2021-08-19 |
Family
ID=69726724
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008696A MX2021008696A (es) | 2019-01-22 | 2020-01-21 | Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton. |
| MX2025013950A MX2025013950A (es) | 2019-01-22 | 2021-07-19 | Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025013950A MX2025013950A (es) | 2019-01-22 | 2021-07-19 | Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12544372B2 (enExample) |
| EP (1) | EP3914250A1 (enExample) |
| JP (3) | JP2022523018A (enExample) |
| KR (1) | KR20210119457A (enExample) |
| CN (3) | CN118453606A (enExample) |
| AU (2) | AU2020213265B2 (enExample) |
| CA (1) | CA3125236A1 (enExample) |
| IL (1) | IL284779A (enExample) |
| MX (2) | MX2021008696A (enExample) |
| TW (1) | TW202042815A (enExample) |
| WO (1) | WO2020154252A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022019846A2 (pt) | 2020-04-03 | 2022-11-22 | Genentech Inc | Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos |
| CN118924759A (zh) * | 2023-05-12 | 2024-11-12 | 武汉人福创新药物研发中心有限公司 | 含有btk抑制剂的组合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013011176A2 (pt) * | 2010-11-05 | 2020-09-01 | Novartis Ag | métodos de tratamento de artrite reumatoide usando antagonistas de il-17 |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| WO2017148837A1 (en) | 2016-02-29 | 2017-09-08 | F. Hoffmann-La Roche Ag | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CN110709702A (zh) | 2017-03-24 | 2020-01-17 | 豪夫迈·罗氏有限公司 | 治疗自身免疫性疾病和炎性疾病的方法 |
-
2020
- 2020-01-21 TW TW109102194A patent/TW202042815A/zh unknown
- 2020-01-21 CN CN202410639156.8A patent/CN118453606A/zh active Pending
- 2020-01-21 CA CA3125236A patent/CA3125236A1/en active Pending
- 2020-01-21 MX MX2021008696A patent/MX2021008696A/es unknown
- 2020-01-21 CN CN202410640589.5A patent/CN118662512A/zh active Pending
- 2020-01-21 KR KR1020217026474A patent/KR20210119457A/ko not_active Ceased
- 2020-01-21 CN CN202080010603.3A patent/CN113423401A/zh active Pending
- 2020-01-21 WO PCT/US2020/014346 patent/WO2020154252A1/en not_active Ceased
- 2020-01-21 EP EP20708271.0A patent/EP3914250A1/en active Pending
- 2020-01-21 AU AU2020213265A patent/AU2020213265B2/en active Active
- 2020-01-21 JP JP2021542124A patent/JP2022523018A/ja active Pending
-
2021
- 2021-07-12 IL IL284779A patent/IL284779A/en unknown
- 2021-07-19 MX MX2025013950A patent/MX2025013950A/es unknown
- 2021-07-21 US US17/381,592 patent/US12544372B2/en active Active
-
2024
- 2024-04-09 JP JP2024062648A patent/JP2024099575A/ja active Pending
-
2025
- 2025-03-17 AU AU2025201888A patent/AU2025201888A1/en active Pending
- 2025-11-10 JP JP2025189049A patent/JP2026041743A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2025201888A1 (en) | 2025-04-03 |
| CN113423401A (zh) | 2021-09-21 |
| US12544372B2 (en) | 2026-02-10 |
| CN118453606A (zh) | 2024-08-09 |
| AU2020213265B2 (en) | 2025-01-16 |
| JP2022523018A (ja) | 2022-04-21 |
| TW202042815A (zh) | 2020-12-01 |
| EP3914250A1 (en) | 2021-12-01 |
| JP2026041743A (ja) | 2026-03-10 |
| CA3125236A1 (en) | 2020-07-30 |
| CN118662512A (zh) | 2024-09-20 |
| KR20210119457A (ko) | 2021-10-05 |
| AU2020213265A1 (en) | 2021-07-22 |
| IL284779A (en) | 2021-08-31 |
| JP2024099575A (ja) | 2024-07-25 |
| US20220047588A1 (en) | 2022-02-17 |
| MX2025013950A (es) | 2026-03-02 |
| WO2020154252A1 (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282468A (en) | 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| AR122786A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
| MX2022002877A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. | |
| MX2021013662A (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. | |
| EP3371762A4 (en) | SYSTEMS AND METHODS FOR POWER-CONTROLLED DYNAMIC GEOFENCE-BASED TARGETING | |
| CR20160379A (es) | Anticuerpos biespecificos anti-il 13/il-17 y sus usos | |
| MX2019000216A (es) | Compuestos, composiciones y metodos para el tratamiento de enfermedades. | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| CL2016000466A1 (es) | Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer. | |
| EA201891620A1 (ru) | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 | |
| BR112017002594A2 (pt) | compostos inibidores de cinase de ligação de tank | |
| MX389307B (es) | Derivados de oxoisoquinolina novedosos | |
| MX2021013118A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| MX2019015348A (es) | Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1). | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| ZA202306172B (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MX2018014577A (es) | Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b. | |
| EP4001273A3 (en) | Aminopyrimidines as alk inhibitors | |
| IL286983A (en) | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor | |
| MX2019007339A (es) | Compuestos de pirazolopirimidina y metodos de uso de los mismos. | |
| MX395110B (es) | Lamina de acero. | |
| LT3972603T (lt) | Sjogreno sindromo gydymo būdai naudojant brutono tirozino kinazės inhibitorių | |
| MX2018010815A (es) | Composiciones y metodos para tratar artritis reumatoide. | |
| MX2021008696A (es) | Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton. | |
| AR110404A1 (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l |